Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT00196612
PHASE3

Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART

Sponsor: ANRS, Emerging Infectious Diseases

View on ClinicalTrials.gov

Summary

The combination of two nucleoside analogues and one protease inhibitor is a highly active antiretroviral therapy (HAART) in HIV infected adults. In those with an undetectable viral load, a once daily combination of FTC, ddI, efavirenz would be easier to take, with less side effects and the same efficacy. The aim of the study was to evaluate if the once daily combination presents the same efficacy than the HAART therapy with less side effects and a better adherence.

Official title: Phase II Randomized Trial Comparing Efficacy and Safety of the Maintenance of a HAART Association Protease Inhibitor Containing Versus a Once Daily Antiretroviral Triple Association, in HIV Adult Patients With Undetectable Viral Load.ANRS 099 ALIZE

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

350

Start Date

2001-04

Completion Date

2004-09

Last Updated

2026-06-15

Healthy Volunteers

No

Conditions

Interventions

DRUG

emtricitabine, FTC (drug)

DRUG

didanosine, ddI (drug)

DRUG

efavirenz (drug)

Locations (1)

Service de Maladies Infectieuses, Hôpital Saint-Louis

Paris, France